Axel Boehnke is the Director Market Access EU North for PTC Therapeutics. He´s fully responsible for all market access aspects, P&R issues, accelerated patient access, early evidence planning, and institutional interactions, focusing on orphan diseases and Gene Therapy. Before, Axel was a Director Market Access at MorphoSys AG, focusing on oncology and especially r/r DLBCL. He has in-depth knowledge and expertise in the specialized business, like Oncology, Autoimmune Diseases, (Ultra) Orphan Diseases, Hepatology, Anti-virals, etc. He also has in track record experience in therapeutic mass markets like cardiovascular or osteoporosis, with respective payer-interactions and contracting. Axel started with Humira at Abbott in national responsibility, headed the Department of Market Access, managed Care at Servier, and served for experience in the biopharmaceutical industry for the last years. He is a Health Economist (University of Cologne) by education and holds a master’s degree in health and medical management (University Erlangen-Nurnberg). Axel is a member of the German Society of Market Access, the German Society of Health Economics, and the EU Market Access & Value Committee at ARM (Alliance for Regenerative Medicine). He published various articles on Benefit Assessment, Market Access, Healthcare-System Issues, Disease Awareness (i.e. in Rheumatoid Arthritis or Psoriasis), and on Claims-Data-Analysis with Real World Evidence.

Jolanda Koenders (F), Director Patient Value & Access, and a.i. Director of Public Affairs in the Netherlands at Takeda. She has over 20 years’ experience in the pharmaceutical industry. With a background in clinical research and medical affairs, Jolanda has broad expertise in Evidence and Value Generation of innovative drugs. In addition, her personality and capabilities ensure long-term strategic relationships with internal- and external customers. Jolanda has a degree in Medical Biologie (MSc) and Health Technology Assessment. In the latter, she obtained practical experience in Pricing & Reimbursement, Market Access, and RWE in her role as Head Pricing & Market Access Novartis the Netherlands, previously delivering the reimbursement dossiers herself as Pricing &Access manager. In her current role, Jolanda manages the Patient Value & Access Managers (HTA and MoH) and Field Market Access managers (hospitals & health insurance companies contracting).

Jack Noble is an analyst working in IQVIA’s European Thought leadership team based in London. His role is to perform data-driven research and analysis across a wide range of pharma market trends and developments with a particular interest in immunology and autoimmune diseases.

Prior experience in competitive intelligence contributes to his multi-faceted view of the pharma market and the multitude of factors that combine to elicit change. Jack holds a master’s degree in Biochemistry from the University of Oxford with a research focus on early-stage drug discovery and structural biology.

Oliver Leatham is a global market access expert and head of Evidence and Access at Certara. His team includes evidence evaluation, HTA, pricing, health economic modeling, and payer engagement. Oliver spe­cialises in market access strategic planning and innovative contracting, with the ability to identify opportunities and negotiate the acceptance of accelerated product approvals. Previously, Oliver worked as the head of pricing and market access for PAREXEL and Head of Market Access for Astellas, combining client-side insights with broader consultancy experience. Oliver has extensive experience in product commercialization, service redesign, payer engagement, and payer marketing. He sat on the AWMSG Steering Committee (HTA body for Wales) and has won awards for partnering with the healthcare providers. His novel approaches to innovative contracting and service redesign, including integrated care pathways and virtual clinics, have been showcased and replicated across a number of health economies in Europe.

Charles-Etienne de Cidrac started his career in the finance industry, working successively in Derivatives and Asset Management. He joined AXA Investment Managers in 1999 and held various positions in Business Development and Sales in France, Germany, and the UK. 

In 2003, he joined the insurance part of the business and was promoted to Head of International Group Insurance. In 2010, he moved to AXA Corporate Headquarters in the newly formed Global Business Line as Health Director. He oversaw Strategy and Development for the Health Business Line of AXA. His role consisted of defining the Health Insurance Strategy of AXA, monitoring the Health Insurance business, and leading initiatives for development and innovation. He was the promoter of the “Health Payer to Health Partner” transformation strategy of AXA. He is currently working in the Group Risk Management of AXA as Health Director. 

He is a graduate of ESCP Europe and Harvard Business School. He is also an alumnus of the Executive Development Program of the IFHP (International Federation of Health Plans). 

In addition to his role at AXA, Charles-Etienne de Cidrac is a member of the Steering Committee of the World Health Organization Community of Practice on Non Communicable Diseases. He teaches “Health Insurance” at Ecole Supérieur d’Assurances in Paris. 

Last, he holds an Independent Director Position at CFJC (Compagnie Financière Jacques Cœur) as a member of the Company’s Supervisory Board.